HEREDITARY CANCER RISK ASSESSMENT

Know your genetic predisposition to various types of cancer

We are bridging science to clinical practice by implementing cutting edge technology to evaluate your hereditary cancer risk. We provide DNA sequencing for targeted panels, allowing us to focus on specific areas of interest at a reduced price and faster delivery time.

Our laboratory’s technology can accommodate small blood sample sizes or buccal swab, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.

HEREDITARY CANCER

Genetic Testing - Hereditary Cancer

GERMLINE MUTATION

The Hereditary Cancer panel targets 108 genes and 281 SNPs that have been previously linked to a predisposition to common and rare forms of cancer such as leukemia, ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer, and skin cancer. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash sample.

The test is intended to identify the variants that are associated with cancer. It is performed as a pre-symptomatic genetic test in order to determine whether persons with a family history of a cancer, but no current symptoms, has gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to gain evidence to confirm variants of association to cancer.

HEREDITARY CANCER TESTING PANELS

ABCB1;ACTRT3;AIMP2;AKT1;ALK;APC;AR;ARHGAP44;ATF1;
ATM;AXIN2;BAG6;BMPR1A;BRAF;BRCA1;BRCA2;BRIP1;
BUB1B;CASC17;CASC8;CCHCR1;CDH1;CDK10;CDKN1A;
CDKN2A;CHEK2;CHRNA3;CLPTM1L;COLCA1;CTD-2194D22.4;
DBNDD1;DICER1;EGFR;EHBP1;ELAC2;EPCAM;ETS2;FGF10;
FGFR4;FH;FLACC1;FLCN;HNF1B;HPDL;HYKK;IRF1;ITGA6;
KLK3;KRAS;LAMA5;LMTK2;MAP2K7;MAP4K2;MAX;MEN1;
MIR5580;MITF;MLH1;MLH3;MLPH;MSH2;MSH6;MSMB;MSR1
MTAP;MT-ND3;MUTYH;MXI1;NF1;NUDT11;PADI6;PALB2;
PCAT2;PDLIM5;PIGU;PMS2;POU5F1B;PTEN;RAD51;
RAD54B;RAD54L;RB1;RET;RFX6;RHPN2;RNA5SP299;
RNASEL;RNU1-19P;RRAS2;RUNX1;SDHB;SDHC;SDHD;
SLC22A3;SMAD4;SMAD7;STK11;TERT;THADA;TMEM127;
TP53;TP63;TSC1;TUBB3;VHL;WEE1;XRCC1;XXYLT1;

RHPN2,CASC8,APC,RNA5SP299,ACTRT3,ATF1,RAD54B,
AIMP2,MLH3,AXIN2,TP53,HPDL,MT-ND3,COLCA1,
MIR5580,LAMA5,SMAD7,BUB1B,MUTYH,PMS2,MSH2,
POU5F1B,BMPR1A,SLC22A3,CDH1,MSH6,MLH1,MAX,
STK11,EPCAM,FBXO11

RRAS2,PALB2,RAD54L,RAD51,BRIP1,CHEK2,MLH3,
BRCA1,BRCA2,EPCAM

TP63,EGFR,IRF1,RB1,BRAF,KRAS,XRCC1,CDKN1A,XXYLT1,
MAP2K7,BAG6,CLPTM1L,WEE1,ETS2,HYKK,CHRNA3

Gastric cancer; Breast Cancer; Lung carcinoma;
Cervical Cancer; Adrenocortica Carcinoma;
Lymphoma; Colorectal Cancer, RET:Lung Cancer,
Thyroid Carcinoma and Endocrine Neoplasia,
SDHB: Gastrointestinal Stromal Tumor;
Paragangliomas; Pheochromocytoma;
Gastrointestinal Cancer

TP53,ABCB1,SDHD,ALK,TSC1,AKT1,CDH1,APC,
ATM,TERT,SDHB,CLPTM1L,CASC8,RET

PCAT2,MSMB,ARHGAP44,PDLIM5,ITGA6,CTD-2194D22.4,
CCHCR1,AR,MXI1,CASC8,THADA,CASC17,FGF10,MLPH,
KLK3,RFX6,FGFR4,HNF1B,ELAC2,NUDT11,LMTK2,EHBP1,
MSR1,RNASEL,SLC22A3

Multiple Endrocrine Neoplasia, Neurofibromatosis,
Melanoma, Parganglioma, Renal Cell Cancer,
Heratoma, Fibrofolliculomas, Plueropulmonary
Blastoma, Gastric Cancer, Von Hippel-Lindau
Syndrome, Paraganglioma-Pheochromocytoma

MAP4K2,CHRNA3,PTEN,FH,CDKN2A,RB1,SDHB,TP53,
RUNX1,CDH1,FLACC1,FLCN,DICER1,MITF,TUBB3,
BMPR1A,SDHC,CDK10,SMAD4,DBNDD1,MTAP,RNU1-19P,
PADI6,RET,MEN1,APC,PIGU,VHL,TMEM127,NF1

REQUISITION FORM AND SAMPLE REPORT

PITUITARY ADENOMA
LUNG
NON-HODGKIN LYMPHOMA
WAGR SYNDROME
DSRCT
NEUROBLASTOMA
COLORECTAL
UTERINE
THYROID
SKIN
TURCOT SYNDROME
ENDOCRINE
ATAXIA-TELANGIECTASIA
URINARY
BREAST
CERVICAL
COWDEN SYNDROME
LYMPHOMA
EYE • AML
MELANOMA
KIDNEY
MESOTHELIOMA
INTRAOCULAR MELANOMA
ENDOMETRIAL
BLOOM SYNDROME
PROSTATE
LEUKEMIA
DENYS-DRASH SYNDROME
RHBDOMYOSARCOMA
FANCONI ANAEMIA
PANCREATIC
STOMACH
BLADDER
VON HIPPEL-LINDAU DISEASE
COSTELLO SYNDROME
RECTAL
GASTROINTESTINAL
VULVAR
SOFT TISSUE SARCOMA
LYNCH SYNDROME II
PEUTZ-JEGHERS SYNDROME
RETINOBLASTOMA
MEDULLOBLASTOMA
LARYNGEAL
PCC
OVARIAN
FALLOPIAN TUBE
CHONDROSARCOMA
PGL
HEAD AND NECK
EWING’S SARCOMA
NEUROFIBROMATOSIS
HODGKIN LYMPHOMA
ADRENOCORTICAL
MYELODYSPLASTIC SYNDROMES
MOSAIC VARIEGATED ANEUPLOIDY
ADENOID CYSTIC CARCINOMA
PERLMAN SYNDROME
ACOUSTIC NEUROMA
SYNOVIAL SARCOMA
ROSTMUND-THOMSON SYNDROME
LI-FRAUMENI SYNDROME
MULTIPLE HEREDITARY EXOSTOSES
BECKWITH-WIEDEMANN SYNDROME
CHRONIC LYMPHOCYTIC LEUKEMIA
ADENOMATOUS POLYPOSIS COIL
WILMS TUMOUR
SALIVARY GLAND
PARATHYROID
JAW
URETHRAL
GASTRIC
PITUITARY
LIVER
OSTEOSARCOMA
RHABDOMYOSARCOMA
TESTICULAR
RHABDOID TUMOURS
BRAIN
ASTROCYTOMA
ESOPHAGEAL

Cancer is triggered by mutations in certain genes of the cell that cause abnormal and uncontrolled cell growth. People can carry gene mutations that are passed down from one generation to the next.
If you were diagnosed with cancer, hereditary cancer assessment may help you determine if your cancer was due to an inherited mutation.
Even if you are not currently diagnosed with cancer, genetic testing can help identify potential inherited risks, especially if another family member was previously diagnosed with cancer.

Knowing genetic predisposition can help you make informed decisions about managing your health care and direct you toward available prevention, monitoring and treatment options.

We strongly recommend that you seek genetic counseling to understand the limitations and possible consequences of this test.

ORDER FORMS • A LETTER FROM OUR PRESIDENT • SPECIMEN REQUIREMENTS • SPECIMEN COLLECTION INSTRUCTIONS • IF GENOMIC DNA IS ALREADY AVAILABLE • SAMPLES OF GENETIC TESTING REPORTS • FAQ

All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Laboratory, LLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing, Clinical Testing, Pharmacogenetic Testing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.